Tenax Therapeutics (TENX) Non-Current Deferred Tax Liability (2015 - 2021)
Tenax Therapeutics recorded quarterly Non-Current Deferred Tax Liability of $211590.0 in Q3 2021, down 11.48% quarter-over-quarter from $239039.0 in Q2 2021.
Tenax Therapeutics' Non-Current Deferred Tax Liability history runs 4 years deep, the most recent figure standing at $211590.0 for Q3 2021.
- In Q3 2021, Non-Current Deferred Tax Liability changed N/A year-over-year to $211590.0; the TTM figure through Sep 2021 stood at $211590.0 (changed N/A YoY), while the FY2020 annual figure was $347.0, changed N/A from the prior year.
- Non-Current Deferred Tax Liability came in at $211590.0 for Q3 2021 at Tenax Therapeutics, down from $239039.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $239039.0 in Q2 2021 to a low of $347.0 in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Tenax Therapeutics | 542.72 Mn | 542.72 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 211,590.00 |
| Sep 30, 2021 | 211,590.00 |
| Jun 30, 2021 | 239,039.00 |
| Jun 30, 2021 | 239,039.00 |
| Dec 31, 2020 | 347.00 |
| Dec 31, 2020 | 347.00 |
| Sep 30, 2016 | 7.96 Mn |
| Sep 30, 2016 | 7.96 Mn |
| Jun 30, 2016 | 7.96 Mn |
| Jun 30, 2016 | 7.96 Mn |
| Dec 31, 2015 | 7.96 Mn |
| Dec 31, 2015 | 7.96 Mn |